Wolfgruber Stella, Sedik Sarah, Klingspor Lena, Tortorano Annamaria, Gow Neil A R, Lagrou Katrien, Gangneux Jean-Pierre, Maertens Johan, Meis Jacques F, Lass-Flörl Cornelia, Arikan-Akdagli Sevtap, Cornely Oliver A, Hoenigl Martin
Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.
Translational Medical Mycology Research Unit, ECMM Excellence Center for Medical Mycology, Medical University of Graz, Graz, Austria.
Mycopathologia. 2024 Aug 1;189(4):70. doi: 10.1007/s11046-024-00871-0.
Invasive candidiasis and candidemia remain a significant public health concern. The European Confederation of Medical Mycology (ECMM) conducted three pan-European multicentre studies from 1997 to 2022 to investigate various aspects of invasive Candida infections. These studies revealed shifting trends in Candida species distribution, with an increase of non-albicans Candida species as causative pathogens, increasing rates of antifungal resistance, and persistently high mortality rates. Despite advancements in antifungal treatment, the persistently high mortality rate and increasing drug resistance, as well as limited drug access in low-income countries, underscore the need for continued research and development in the treatment of Candida infections. This review aims to summarize the findings of the three completed ECMM Candida studies and emphasize the importance of continued research efforts. Additionally, it introduces the upcoming ECMM Candida IV study, which will focus on assessing candidemia caused by non-albicans Candida species, including Candida auris, investigating antifungal resistance and tolerance, and evaluating novel treatment modalities on a global scale.
侵袭性念珠菌病和念珠菌血症仍然是一个重大的公共卫生问题。欧洲医学真菌学联合会(ECMM)在1997年至2022年期间开展了三项泛欧洲多中心研究,以调查侵袭性念珠菌感染的各个方面。这些研究揭示了念珠菌物种分布的变化趋势,非白色念珠菌作为致病病原体的比例增加,抗真菌耐药率上升,死亡率持续居高不下。尽管抗真菌治疗取得了进展,但死亡率持续居高不下、耐药性不断增加,以及低收入国家药物可及性有限,凸显了在念珠菌感染治疗方面持续开展研究和开发的必要性。本综述旨在总结ECMM完成的三项念珠菌研究的结果,并强调持续研究努力的重要性。此外,还介绍了即将开展的ECMM念珠菌IV研究,该研究将重点评估由非白色念珠菌引起的念珠菌血症,包括耳念珠菌,调查抗真菌耐药性和耐受性,并在全球范围内评估新型治疗方式。